Repligen Corporation’s recently made public that its Director DAWES KAREN A unloaded Company’s shares for reported $0.15 million on Aug 29. In the deal valued at $171.38 per share,850 shares were sold. As a result of this transaction, DAWES KAREN A now holds 83,741 shares worth roughly $ 14.72 million.
Then, Madaus Martin D bought 500 shares, generating $78,090 in total proceeds. Upon buying the shares at $156.18, the Director now owns 1,611 shares.
Before that, Madaus Martin D bought 500 shares. Repligen Corporation shares valued at $79,595 were divested by the Director at a price of $159.19 per share. As a result of the transaction, Madaus Martin D now holds 1,111 shares, worth roughly $0.2 million.
Wells Fargo initiated its Repligen Corporation [RGEN] rating to an Overweight in a research note published on Friday, July 20, 2023; the price target was $185. PT values the company’s stock at a premium of 5.01 to its Friday closing price.
Price Performance Review of RGEN
On Friday, Repligen Corporation [NASDAQ:RGEN] saw its stock jump 1.05% to $175.74. On the same session, the stock had its day’s lowest price of $175.105, but rose to a high of $179.27. Over the last five days, the stock has gained 6.66%. Repligen Corporation shares have risen nearly 3.80% since the year began. Nevertheless, the stocks have fallen -19.89% over the past one year. While a 52-week high of $235.06 was reached on 02/16/23, a 52-week low of $134.64 was recorded on 07/06/23. SMA at 50 days reached $161.30, while 200 days put it at $168.79. A total of 0.41 million shares were traded, compared to the trading of 0.66 million shares in the previous session.
Levels Of Support And Resistance For RGEN Stock
The 24-hour chart illustrates a support level at 174.14, which if violated will result in even more drops to 172.54. On the upside, there is a resistance level at 178.31. A further resistance level may holdings at 180.87. The Relative Strength Index (RSI) on the 14-day chart is 62.01, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 6.98, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 16.00%. Stochastics %K at 83.32% indicates the stock is a selling.
How much short interest is there in Repligen Corporation?
A steep rise in short interest was recorded in Repligen Corporation stocks on Aug 14, 2023, growing by 10000.0 shares to a total of 5.4 million shares. Yahoo Finance data shows the prior-month short interest on Jul 13, 2023 was 5.39 million shares. There was a rise of 0.19%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 10.95% of the overall stock float, the days-to-cover ratio (short ratio) rose to 8.61.
Repligen Corporation [RGEN] – Who Are The Largest Shareholders?
In filings from The Vanguard Group, Inc., it is revealed that the company now owns 4,982,241 shares, or roughly 8.95% of the outstanding RGEN shares. In other words, the investor’s shares have fallen by -23,492 from its previous 13-F filing of 5005733.0. Additionally, BlackRock Fund Advisors increased 0.62% of its stake after which the total value it holdings stand at $850,068,820, while T. Rowe Price Associates, Inc. reduced -1.19% of its stake to hold $630.54 million in the firm. Over the last quarter, Fidelity Management & Research Co purchased 397,397 shares of Repligen Corporation, while SSgA Funds Management, Inc. bought 14,647 shares. At present, Sands Capital Management LLC is holding 1,594,179 shares valued at $273.5 million. BlackRock Advisors LLC owned 1,582,751 shares of the company at the time of its most recent 13F filing, worth $271.54 million.
According to FactSet, Repligen Corporation’s share price will average $197.62 in the next year, based on opinions of analysts polled by the firm. This is up nearly 15.0 percent from its previous closing price of $173.91. Analysts expect Repligen Corporation stock to reach the higher price of $240.00, while the lowest price estimate is $165.00. However, 13 analysts have rated RGEN stock as a Buy in their predictions for 2023.